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David Price2, Nicholas J Kenyon1,2 and Nicholas Stollenwerk1,2*Abstract
Neuromuscular blocking agents (NMBAs), or “paralytics,” often are deployed in the sickest patients in the intensive
care unit (ICU) when usual care fails. Despite the publication of guidelines on the use of NMBAs in the ICU in 2002,
clinicians have needed more direction to determine which patients would benefit from NMBAs and which patients
would be harmed. Recently, new evidence has shown that paralytics hold more promise when used in carefully
selected lung injury patients for brief periods of time. When used in early acute respiratory distress syndrome
(ARDS), NMBAs assist to establish a lung protective strategy, which leads to improved oxygenation, decreased
pulmonary and systemic inflammation, and potentially improved mortality. It also is increasingly recognized that
NMBAs can cause harm, particularly critical illness polyneuromyopathy (CIPM), when used for prolonged periods or
in septic shock. In this review, we address several practical considerations for clinicians who use NMBAs in their
practice. Ultimately, we conclude that NMBAs should be considered a lung protective adjuvant in early ARDS and
that clinicians should consider using an alternative NMBA to the aminosteroids in septic shock with less severe lung
injury pending further studies.
Keywords: Neuromuscular blocking agents, Neuromuscular nondepolarizing agents, Polyneuropathies, Respiratory
distress syndrome, Adult, Cisatracurium, Status asthmaticus, Shock, SepticIntroduction
Since the publication of the 2002 guidelines for the use of
neuromuscular blocking agents (NMBAs) in the critically
ill, titled “Clinical practice guidelines for sustained neuro-
muscular blockade in the adult critically ill patient” [1],
there has been new evidence that clinicians must reconcile
with their current understanding of which patients should
receive NMBAs. Whereas NMBAs are used in the inten-
sive care unit (ICU) for a variety of indications, in this
review we focus on the use of NMBAs to facilitate mech-
anical ventilation, especially in acute respiratory distress
syndrome (ARDS). This review begins by contrasting the
2002 guidelines with current practice patterns related to
NMBAs. In the “Promising Uses” section, we present the
newest evidence to support the use of NMBAs in early
ARDS with a focus on possible mechanisms for these
results. We ultimately suggest clinicians to consider
NMBAs as part of a lung protective strategy, especially in* Correspondence: nicholas.stollenwerk@ucdmc.ucdavis.edu
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in any medium, provided the original work is ppatients with more severe lung injury. In the section titled
“Cause for Concern,” we evaluate the evidence linking
NMBAs to CIPM in different disease states. Specifically,
we use human as well as preclinical studies to raise con-
cern about the routine use of NMBAs, especially aminos-
teroid NMBAs, in septic shock. Finally, we synthesize this
data for clinicians by offering a suggested alternative
algorithm to the one presented in the 2002 guidelines.
Clinical pharmacology of NMBAs
Neuromuscular blocking agents act on the skeletal
muscle postsynaptic nicotinic acetylcholine (ACh) recep-
tor. This class of medications is broken down into de-
polarizing and nondepolarizing blockers. Depolarizing
NMBAs, the prototype being succinylcholine, are rarely
used in critically ill patients because of the risk of hyper-
kalemia and malignant hyperthermia and will not be fur-
ther addressed in this review. Nondepolarizing NMBAs
competitively bind the alpha subunits of the intra-
junctional ACh receptor on the skeletal muscle postsy-
naptic membrane leading to inhibition of current
through the receptor and thus flaccidity [2]. The clinical
pharmacology of these agents is presented in Table 1.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Clinical pharmacology of nondepolarizing neuromuscular blocking agents
NMBA Peak effect
(min)
Recovery
(min)
Metabolism Renal
elimination (%)
Biliary
elimination (%)
Vagolytic
effect
Histamine
release
Critical illness
polyneuromyopathy
Benzylisoquinolinium
Atracurium 2-3 30-60 Hoffman Elimination (blood) 5-10 None None + +
Cisatracurium 1-7 40-90 None None None None +
Aminosteroid
Pancuronium 2-3 80-180 Liver 40-70 10-15 +++ None +++
Rocuronium 1-2 20-60 10-30 50-75 + None +
Vecuroniurn 2-3 40-60 15-50 35-50 None None +++
+ minimal, ++ moderate, +++ marked.
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The 2002 guidelines identify indications for NMBAs and
offer a simple algorithm for selecting an agent [1].
Recent surveys and cohort studies of clinical practice show
a more detailed picture of actual NMBA use. Whereas the
agents used and the indications for use are similar to the
guidelines, these studies show a practice pattern of
NMBAs used disproportionately on the sickest patients.
Pancuronium, rocuronium, and vecuronium are the
most commonly used NBMAs [3,4]. In their survey of
U.S. intensivists, Rhoney and Murry [3] found 50% of
respondents use vecuronium frequently or routinely ver-
sus 25% who use pancuronium and 6.4% who use rocur-
onium. When asked about decision-making, clinicians
responded that they were more likely to choose a NMBA
based on their clinical experience and preference then
on patient-specific factors. The surveys found that surgi-
cal ICU patient are more likely to receive pancuronium,
whereas medical ICU patients are more likely to receive
vecuronium. As for administration, clinicians are more
likely to give vecuronium and cisatracurium as continu-
ous infusions, whereas all other agents are mostly given
as intermittent boluses [3].
The indications reported by Rhoney and Murry [3]
and Mehta et al. [4] for NMBA use are consistent with
the 2002 guidelines (Figure 1). Beyond endotracheal
intubation, the facilitation of mechanical ventilation is
the most common indication for NMBAs with half
reporting routine or frequent use of NMBAs for this rea-
son. Less commonly cited indications include dosing to
decrease metabolic demand, control of intracranial pres-
sure, and decrease agitation. Within the category of
facilitating mechanical ventilation, the most cited rea-
sons included use of unconventional ventilation (35%),
hypoxemia (25%), reduced compliance (25%), patient
ventilator asynchrony (18%), and hypercapnia (15%) [4].
Arroliga et al. [5] went beyond surveys and looked at a
cohort of international patients to determine which
patient’s received NMBAs; 13% of patients in this cohort
received a NMBA. Use was associated with patients on
full ventilatory support with an odds ratio (OR) of 3.68and 95% confidence interval (CI) of 2.38-5.7, requiring
permissive hypercapnia (OR 4.49, CI 2.53–7.95), prone
ventilation (OR 4.36, CI 2.33–8.12), with higher pres-
sures, higher positive end-expiratory pressure (PEEP),
and patients with ARDS (OR 2.01, CI 1.43–2.83). A sub-
sequent study by Arroliga et al. [6] focused on only
ARDS patients and similarly showed use associated with
sicker patients. Intensity of NMBA use in this popula-
tion was associated with higher acute physiology and
chronic health evaluation III (APACHE III) score, higher
plateau pressures, larger Alveolar-arterial oxygen con-
centration (A-a) gradient, and lower tidal volumes.
Despite firm recommendation that NMBA effect
should be monitored in the ICU [1], in practice, the use
of regular monitoring and daily NMBA interruption pro-
tocols remains variable. Depending on the study, 25-50%
of intensivists report protocols for NMBA use in their
ICUs. The rate of monitoring with train of four (TOF) is
better with up to 84% using electrical monitoring [3,4].
Finally, the duration of NMBA use is variable but
favors shorter duration of use. Arroliga et al.’s inter-
national study [5] of mechanically ventilated patients
reported median duration of use to be 2 days. In acute
lung injury and ARDS patients, however, NMBAs are
used for even shorter periods [6].
Promising uses: ARDS
There is growing evidence to support the selective use of
NMBAs in early ARDS. In the past decade, three pro-
spective randomized trials have evaluated the use of
NMBAs in ARDS [7-9]. Before these trials, NMBAs were
thought to be beneficial in ARDS [2,10], but there was
insufficient evidence to support a mechanism or demon-
strate a benefit.
Improve oxygenation
Gainnier et al. [7] randomized 56 medical and surgical
ICU patients with ARDS in four French hospitals to 48
hours of cisatracurium or placebo to evaluate the primary
endpoint of improved oxygenation within 120 hours of
randomization. Statistically significant improvement in
Figure 1 Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Reprint with permission from [1].
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48 hours and was sustained through the primary endpoint
of 120 hours (p = 0.021). Of note, Gainnier’s experimental
group abolished all TOF responses; deeper paralysis than
is called for by the guidelines [1]. Forel et al. [8] found a
similar improvement in oxygenation as a secondary end-
point. The time to effect in these studies differ from
Coggeshall’s [10] observation of immediate improvement
in oxygenation after administration of pancuronium to a
patient with severe ARDS.
The hypothetical mechanism for this sustained improve-
ment in oxygenation is likely a combination of reduced
oxygen consumption [11,12] as well as homogenous distri-
bution of PEEP and tidal volume limiting disproportionate
barotrauma [9] and worsening of ARDS. These effects
appear to occur in the absence of improved pulmonary
mechanics [13,14]. Reduced oxygen consumption was pre-
viously postulated as a mechanism for improved oxygen-
ation in a severe ARDS patient with an arterial partial
pressure of oxygen to inspired oxygen (P:F) ratio of 58 and
elevated respiratory rate [10]. With each dose of NMBA,
the patient’s respiratory rate decreased and oxygenation
improved. This effect was later quantified in eight healthy
adults whose oxygen consumption decreased 18% as theywere transitioned from continuous positive airway pres-
sure (CPAP) alone to invasive ventilation with a NMBA
[11]. Reduced oxygen consumption is an immediate effect,
however, whereas the improvements in oxygenation else-
where reported were seen after 24 hours [7,8,15]. This
delayed improvement in oxygenation is better explained
by slowing of disease progression. Papazian et al. [9] found
decreased barotrauma in patients receiving NMBAs as
opposed to the original lung protective study [15], whereas
despite lower tidal volume in the experimental group, the
amount of barotrauma was similar in each group. This
decreased stress likely potentiates the lung protective
effect of low tidal volume, because it leads to more
homogenous distribution of ventilation [16].
Decrease inflammatory response
One of the more exciting findings is that NMBAs may
decrease the inflammatory response associated with
ARDS. Forel et al. [8] demonstrated this result in a 2006
study, which randomized 36 patient to 48 hours of NMBA
versus placebo and compared their bronchoalveolar lavage
(BAL) and serum at 0 and 48 hours for statistical differ-
ences in inflammatory markers. Cisatracurium was again
administered to the experimental group to abolish train of
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nificant decrease in interleukin-1 (IL-1), IL-6, and IL-8 in
the BAL and IL-1 and IL-6 in the serum. No difference
was found in the BAL or serum level of tumor necrosis
factor-alpha or the BAL cell differential.
Although the mechanism is unknown, it is possible
that NMBAs eliminate excessive intrathoracic pressure
changes and decrease alveolar overdistention, a phe-
nomenon that is known to release proinflammatory cyto-
kines in animal models [17-21]. IL-6 levels measured in
the original lung protective trial [15] were significantly
lower in the lung protective group. This decrease in
inflammatory cytokines with lung protective tidal volumes
was previously studied [22,23], with Parson et al. showing
mortality benefit with decreased IL-6 levels. With the
administration of a NMBA and the decreased mechanical
stress and improved homogenation discussed above, there
is less inflammatory response and less likelihood of this
inflammation becoming systemic.
Improve mortality
In 2010, Papazian et al. [9] was the first to show a mor-
tality benefit with early use of NMBAs in ARDS. This
result was in contrast to a prior retrospective cohort
study [6] that showed no mortality benefit. Building on
the work by Gainnier and Forel, Papazian randomized
340 patients to 48 hours of cisatracurium versus placebo
and was able to show a 90-day mortality benefit after
adjusting for baseline P:F ratio, simplified acute physiology
score II (SAPS II), and plateau pressure (hazard ratio 0.68,
CI 0.48–0.98, p = 0.04). There was not, however, a signifi-
cant difference in crude mortality between the study
groups (31.6% in the cisatracurium group vs. 40.7% in the
control group, p = 0.08). Beyond the improved oxygen-
ation and anti-inflammatory mechanism mentioned above,
the etiology of this adjusted mortality benefit from
NMBAs can be inferred from the subgroup analysis.
Patients in the cisatracurium group had more ventilator-
free days (53 vs. 45, p = 0.03), more days outside the ICU
(48 vs. 40, p = 0.03), less barotrauma, as well as more days
without coagulation abnormalities, renal failure, and hep-
atic dysfunction. The greatest benefit, moreover, was seen
with a P:F ratio less than 120. Given the weakly significant
p value associated with adjusted mortality, it is worth not-
ing that this study was underpowered for the mortality
rate it ultimately saw in its control group.
Cause for concern: critical illness polyneuromyopathy
Critical illness polyneuromyopathy (CIPM) is a term that
describes two separate diseases: critical illness polyneur-
opathy (CIP) and critical illness myopathy (CIM).
Whereas CIP mainly affects motor and sensory nerve
fibers leading to degeneration of the skeletal muscle,
CIM directly affects myosin leading to muscle necrosis.In the critically ill, CIP portends a worse prognosis than
CIM [24]. CIP has been associated with increased
in-hospital mortality [25], longer duration of mechanical
ventilation [26,27], increased days in the ICU [28], and
longer hospital stays [26]. In practice, CIM and CIP can
overlap and often are indistinguishable without electro-
myographic (EMG) studies and muscle biopsy. For the
purpose of this review, CIPM will be used to describe
clinically significant weakness that is not further defined,
whereas CIP and CIM will be used when authors pro-
vide sufficient EMG, muscle biopsy, and clinic data on
sensory involvement to make a distinction.
CIPM has haunted physicians using NMBAs since this
debilitating side effect was described in severe asthmatic
patients who were receiving both high-dose steroids and
NMBAs [26,27,29]. Despite legitimate concerns with
prolonged use of NMBAs, there is little evidence that
using NMBAs for less than 48 hours causes CIPM. The
relationship between NMBAs and CIPM is not that sim-
ple, however, but a number of animal and human studies
have helped to illuminate the connection and alert clini-
cians about which patients are at highest risk for CIPM.
CIPM with Benzylisoquinolinium versus Aminosteroid
NMBAs
As seen in Table 2, aminosteroid NMBAs have been more
strongly implicated in CIPM than the benzylisoquinoli-
nium compounds. Aminosteroid NMBAs have been asso-
ciated with CIPM in patients receiving corticosteroids
[26,27,30], sepsis with multiorgan failure [25,31], in mul-
tiple animal models of NMBA use [32,33], and with both a
dose- and time-dependent relationship [27,31,34]. Con-
versely, only case studies of benzylisoquinolinium agents
with concomitant corticosteroids for at least 6 days have
linked this class of NMBAs to CIPM [35-38]; a link that
could be explained by use of corticosteroids alone. In their
studies of 48 hours of cisatracurium in ARDS, moreover,
Papazian, Gainnier, and Forel found no association
between cisatracurium and CIPM.
CIPM with NMBAs in general population
In a general population of ICU patients, de Jonghe et al.
[44] found a CIPM incidence of 25% but no association
between NMBAs and CIPM. Rather, CIPM was associated
with corticosteroid administration, duration of mechanical
ventilation, and number of days with dysfunction in more
than two organs. Beyond this study, however, within sub-
groups of patients receiving NMBAs, specifically patients
with ARDS, severe asthma on steroids, and septic shock,
the association with CIPM is more variable.
CIPM with NMBAs in ARDS
Papazian, Gainnier, and Forel all used NMBAs for 48
hours in patients with either ALI or ARDS and found no
Table 2 Studies of NMBAs related to prolonged weakness, CIP, and CIM
NMBA Author Subjects Study design Motor Sensory EMG Muscle biopsy Prolonged weakness, CIP, and CIM
Benzylisoquinolinium
Cisatracurium
Human studies
Fodale et al. [36] 1 Case report Y N Y N NMBA and CS for 7 days in patient with
chest wall trauma led to quadriplegia
consistent with CIM.
Davis et al. [35] 1 Case report Y N N N NMBA and CS for 6 days with 6 additional
days of NMBA in 45-year-old with ARDS
led to CIM.
Atracurium
Human studies
Tousignant et. al.
[38]
1 Case report Y N Y N 18-year-old asthmatic with 7 days of
NMBA and CS develops acute
quadriparesis 3 days after cessation of
NMBA consistent with CIM.
Meyer et al. [37] 2 Case report Y N Y N 38-year-old receiving CS and 8 days of
NMBA developed CIM. 25-year-old with
good pastures receiving CS and NMBA for
6 days develop CIM.
Aminosteriods
Pancuronium
Human studies
Behbehani et al.
[26]
86 Retrospective
Cohort
Y N Y N Asthmatics receiving NMBA and CS.
Pancuronium, vecuronium used in 30
with 9 developing CIM. All nine received
pancuronium.
de Lemos et al.
[39]
30 Prospective
Observational
Cohort
Y N Y N Study of recovery time in continuous
infusion versus bolus groups. Six patients
with CIM, five of which received
continuous infusion. No statistical
difference in total dose between groups.
Giostra et al. [30] 9 Prospective
Cohort
Y Y Y Y Over 2 years, nine patients with
respiratory failure requiring mechanical
ventilation and NMBA developed CIP.
Eight of nine received concomitant NMBA
and CS.
Rocuronium
Animal Studies
Maes et al. [40] Rat / 27 Prospective
Randomize
N/A N/A Y Y 1 dose of CS added to 24 hours of NMBA
results in decreased CIM of diaphragm
than NMBA alone.
Testelmans et al.
[33]
Rat / 24 Prospective
Randomize
N/A N/A Y Y 24 hours of rocuronium associated with
worse CIM than cisatracurium.
Testelmans et al.
[32]
Rat / 34 Prospective
Randomize
N/A N/A Y Y 24 hours of NMBA associated with
increased CIM than mechanical
ventilation alone.
Vecuronium
Human Studies
Garnacho-
Montero
et al. [25]
73 Prospective
Cohort
Y Y Y N In septic cohort with more than 2 organ
failure, 9 of 10 patients who got NMBA
developed CIP. 6 received vecuronium
and 3 received atracurium
Rudis et al. [34] 77 Prospective
Randomized
Single-Blind
Y N Y N Use of peripheral nerve stimulator
resulted in half dose of NMBA given. 16
patients with prolonged blockade and 4
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with CIP. More prolonged blockade and
CIP in group with more NMBA.
Prielipp et al. [41] 58 Prospective
Randomized
Double-Blind
Y Y Y Y Prolonged recovery in 13 patients with
vecuronuim versus 2 with cisatracurium
(p=0.002). CIP in 1 vecuronuim patient.
Douglass et al.
[27]
25 Prospective
Cohort
Y N N N 22 patients received NMBA and CS. 9
developed CIM. CIM associated with time
ventilated and dose of NMBA received.
Kupfer et al. [31] 28 Prospective
Cohort
Y 1/5 Y N 50% of patient without sepsis or
multi-organ failure with more than 6
hours of NMBA infusion developed
weakness. 1 CIPM, 4 CIM. CIPM and CIM
ssociate with increase dose.
Danon et al. [42] 1 Case report Y N N Y 20 year old asthmatic who received CS
and NMBA for 10 days developed CIM.
Y, yes; N, no; N/O, not obtained; CS, corticosteroid; CIP, critical illness polyneuropathy; CIM, critical illness myopathy; CIPM, critical illness polyneuromyopathy;
NMBA, neuromuscular blocking agent; ARDS, acute respiratory distress syndrome [25-27,30-38,44-48].
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study, at 28 days, the difference in patients without ICU-
acquired paresis was not statistically significant between
the cisatracurium and control group (p = 0.64). No stud-
ies have evaluated incidence of CIPM in ARDS when
NMBAs are used for more than 48 hours.Figure 2 Suggested modifications to clinical practice guidelines for su
Bolded text represents suggested modifications to 2002 guidelines.CIPM with NMBAs in severe asthmatics receiving
corticosteroids
The concomitant use of NMBAs and corticosteroids has
been shown to place patients at high risk for CIM. If
clinically necessary, however, limiting the duration of
using these medications together can minimize CIM.stained neuromuscular blockade in the adult critically ill patient.
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asthmatics receiving corticosteroids and NMBAs,
Douglass et al. and Leatherman et al. [27,29], found the
incidence of CIM to be roughly one third. When time
paralyzed is factored in, however, these numbers tell a
different story. In the Douglass study, the patients with
CIM were paralyzed for an average of 5 days compared
with an average of 1 day in the CIM-free group. More-
over, in the Leatherman study, when CIM group was
broken down by time paralyzed, 6% of patients paralyzed
less than 24 hours developed CIM versus 38% paralyzed
for 24 to 48 hours and 85% paralyzed for more than 48
hours. In neither of these studies was incidence of CIM
adjusted for severity of underlying illness. In contrast,
when Behbehani et al. [26] analyzed a cohort of severe
asthmatics patients receiving corticosteroids and adjusted
for severity of underlying illness, they found no association
between use of NMBAs and CIM. They did, however, find
an association between duration of muscle paralysis and de-
velopment of CIM with an odds ratio of 2.1 per day of
NMBA used.
CIPM with NMBAs in septic shock
The evidence linking the routine use of NMBAs in sep-
tic shock with the development of CIP and CIPM is con-
cerning. Sepsis itself is a risk factor for CIPM with rates
reported as high as 70% [28]. Garnacho-Montero et al.
[25] specifically looked at a cohort of septic patients with
greater than two MODS who required mechanical venti-
lation for more than 10 days to evaluate the impact of
CIP on outcomes. The incidence of CIP was 63% at day
10. Among the ten septic patients to receive NMBAs,
however, the incidence of CIP was 90%. Six of the nine
patients with CIP received vecuronium, whereas the
other three received atracurium. The odds ratio for risk
of CIP with use of NMBAs in their cohort was 16 (OR
16.32; 95% CI 1.34-199; p = 0.0008). Of note, the one pa-
tient without CIP received less total NMBA than the
three patients with CIP. In Forel’s study of NMBAs in
ARDS [8], moreover, 2 of 36 patients developed CIP: 1
who received cisatracurium and the other who did not.
Both of these patients had ARDS from septic shock. Sepsis
appears to be such a potent risk factor for CIPM that use
of an additional agent with potential to cause CIPM, such
as NMBAs, places patients at substantial risk for CIPM.
Animal model studies support this clinical finding of
sepsis as a potent contributor to CIPM. Ochala et al. [45]
intubated, sedated, and induced sepsis through E. coli
endotoxin in young piglets for 5 days to evaluate the dif-
ferent contribution that mechanical ventilation, corticos-
teroids, NMBAs, and sepsis play in the pathogenesis of
CIM. Whereas mechanical ventilation was consistently
shown to decrease muscle compound muscle action
potential amplitudes (CMAP), sepsis was independentlyassociated with a dramatic decrease in force generation
capacity, a finding not seen with NMBAs. It should be
noted that when all interventions were involved (intubated
and sedated, septic, corticosteroids, and NMBA), import-
antly, the degree of decline in CMAP was greatest. This
finding supports the idea that NMBAs administered in
the setting of sepsis are more likely to cause CIPM than
sepsis alone. Rossignol et al. [46] found similar findings
in septic rats that were not intubated. After 10 days of sep-
sis, the fast-twitch extensor digitorum longus muscle has
a smaller cross-sectional area, increased fatigability, and
reduction in maximal twitch contraction among other
abnormalities.
Given the concerning evidence linking septic shock
and NMBAs with CIPM presented above, we believe
that clinicians should use caution when considering
NMBAs in this patient population. Moreover, the strong
association between aminosteroid NMBAs and CIPM
described above and shown in Table 2 should further
raise concern about using aminosteroid NMBAs in these
patients already at high risk for CIPM.
Sedation and monitoring of NMBAs
Before the initiation of NMBAs, clinicians must ensure
appropriate sedation and patient comfort. Practically,
clinicians can provide sedation and analgesic until the
patient is unconscious before administration of an
NMBA [1]. Once properly sedated, accurate monitoring
of NMBAs allows clinicians to get the maximum benefit
while limiting the amount of medication used. Increased
dose and duration of NMBA is associated with signifi-
cant morbidity [25-27,29], so it is in the patient’s best
interest to given the least amount of NMBA possible.
Secondary to underlying organ dysfunction and intrinsic
characteristics, patients require different amounts of
NMBA to achieve the same level of paralysis. For
example, Circeo et al. [47] found that patients with mul-
tiorgan failure (MOF) required less than half the dose of
NMBA than patients without MOF to achieve same level
of paralysis. In a study of septic rats, conversely, atracur-
ium has a shorter onset and wore off quicker than in
nonseptic rats [46].
The depth of paralysis, however, remains controversial.
Targeting a TOF of two of four rather than zero of four
has been shown to be beneficial. In a prospective,
randomize, open-labeled study [48] of 102 ARDS
patients randomized to shallow or deep paralysis for a
median duration of 31.4 (range 1.6-650.6) and 28.9
(range 3.1-219.7) hours respectively, the shallow paraly-
sis group had a higher P:F ratio, lower plateau pressure,
and perhaps most importantly, received less total NMBA
and had shorter recover time. Moreover, the 2002 guide-
lines, as discussed above, also recommend targeting a
TOF of one to two of four. Conversely, in their studies
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mortality with NMBAs in early ARDS, Gainnier, Forel,
and Papazian all targeted zero of four.
Areas for future study
This paper brings to light multiple clinical questions that
require further experimentation to clarify. To begin with,
could the improvements in oxygenation, inflammation,
and mortality shown in studies of NMBAs in ARDS by
Gainnier, Forel, and Papazian been achieved with less
paralytic? Although there is some evidence [47,48] as
well as guidelines [1] available that targeting a TOF of
two of four is beneficial, these authors chose a greater
depth of paralysis. Perhaps the small mortality benefit
shown by Papazian would have been larger with less
paralytic. Moreover, we offered evidence to support a
mechanism for the improvement in oxygenation and in-
flammation seen in the studies by Gainnier and Forel,
respectively, but additional studies are needed to investi-
gate these hypothetical mechanisms.
More studies are needed to address the use of NMBAs
in patients with sepsis, and more specifically, septic
shock. The animal studies and the few human studies dis-
cussed here suggest an unacceptable level of CIPM when
NMBAs are used in septic shock, especially aminosteroid
NMBAs. Further, prospective, randomized studies that
evaluate aminosteroid NMBAs versus benzylisoquinoli-
nium NMBAs in septic shock and the association with
CIPM are needed to bolster our concern.
Conclusions
Achieving a mortality benefit from use of NMBAs comes
with a small margin for error. Future studies of these
agents need to build on the body of evidence suggesting
that NMBAs can improve outcomes in patients with
lung injury. The following conclusions should be kept in
mind.
1. Use of NMBAs should be targeted. NMBAs offer a
benefit in ARDS, whereas there is evidence that they
may cause harm in septic shock. Within the broad
category of ARDS, patients with a P:F ratio less than
120 have the greatest mortality benefit. To help
clinicians select the proper NMBA, in Figure 2 we
offer an algorithm for selecting a NMBA, which
builds on the 2002 guidelines by incorporating the
evidence presented in this review.
2. The less NMBA used the better. This conclusion
applies more to time paralyzed than to depth of
paralysis. The use of NMBAs for less than 48 hours
is supported by more evidence than any other
conclusion related to NMBAs. There is evidence,
moreover, that less than 48 hours of NMBAs, either
24–36 hour may be even more beneficial.3. Beware of potentiation of effect. Whereas
corticosteroids and aminoglycosides are known to
potentiate CIPM, of equal importance is presence of
sepsis with MOF. Clinicians must balance the risk-
benefit ratio based on a complete understanding of
the patient’s medications and clinical course.
Extrapolating the findings of recent positive studies
in ARDS to all lung injury patients requiring
mechanical ventilation is difficult, but the answer to
this challenge represents the future of “paralytics” in
the ICU.
Endnotes
No endnotes included in this review.
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